These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34706253)

  • 21. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular classification of myeloproliferative neoplasms-pros and cons.
    Qureshi M; Harrison C
    Curr Hematol Malig Rep; 2013 Dec; 8(4):342-50. PubMed ID: 24091831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
    Grinfeld J; Nangalia J; Baxter EJ; Wedge DC; Angelopoulos N; Cantrill R; Godfrey AL; Papaemmanuil E; Gundem G; MacLean C; Cook J; O'Neil L; O'Meara S; Teague JW; Butler AP; Massie CE; Williams N; Nice FL; Andersen CL; Hasselbalch HC; Guglielmelli P; McMullin MF; Vannucchi AM; Harrison CN; Gerstung M; Green AR; Campbell PJ
    N Engl J Med; 2018 Oct; 379(15):1416-1430. PubMed ID: 30304655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.
    Perricone M; Polverelli N; Martinelli G; Catani L; Ottaviani E; Zuffa E; Franchini E; Dizdari A; Forte D; Sabattini E; Cavo M; Vianelli N; Palandri F
    Oncotarget; 2017 Jun; 8(23):37239-37249. PubMed ID: 28422729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
    Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
    Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic myeloproliferative diseases.
    de Lacerda JF; Oliveira SN; Ferro JM
    Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden.
    Lee Tokar L; Crotty G; O'Keeffe D; Langabeer SE
    Blood Cells Mol Dis; 2021 Sep; 90():102593. PubMed ID: 34217938
    [No Abstract]   [Full Text] [Related]  

  • 29. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    Fröhling S; Scholl C; Gilliland DG; Levine RL
    J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.
    Guglielmelli P; Nangalia J; Green AR; Vannucchi AM
    Am J Hematol; 2014 May; 89(5):453-6. PubMed ID: 24458922
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
    Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
    Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.
    Syeed N
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3611-3615. PubMed ID: 31870101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in elucidation of molecular pathophysiology and its application in therapeutic decision-making for myeloproliferative neoplasms.
    Takenaka K
    Int J Hematol; 2020 Feb; 111(2):180-181. PubMed ID: 31907735
    [No Abstract]   [Full Text] [Related]  

  • 35. [Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].
    Dong L; Shen XL; Wei W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1532-4. PubMed ID: 26524072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
    Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
    Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.
    Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R
    Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice.
    Lee J; Godfrey AL; Nangalia J
    Blood Rev; 2020 Jul; 42():100708. PubMed ID: 32571583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms.
    Luo M; Tian T; Zhang Y; Zhang X; Xie J; Xu J; Ren W; Tian C; Wang J; Tan Y; Wang H; Chen X
    Int J Lab Hematol; 2021 Jun; 43(3):e110-e113. PubMed ID: 33244866
    [No Abstract]   [Full Text] [Related]  

  • 40. Single-cell methods in myeloproliferative neoplasms: old questions, new technologies.
    O'Sullivan JM; Mead AJ; Psaila B
    Blood; 2023 Jan; 141(4):380-390. PubMed ID: 36322938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.